CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

The Food and Drug Administration (FDA) has approved Spravato, a nasal spray developed by Johnson & Johnson, as a standalone ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression ...